Lawrence Coolidge
Director
Board of Directors
Minerva Biotechnologies
United States of America
Biography
Mr. Coolidge joined the Loring, Wolcott & Coolidge Office in 1962. Members of the Loring, Coolidge and Weld families old-money names in Boston have their estates here. With $3.5 billion under management, Coolidge concentrates on 50 high-quality growth stocks. They favor very low turnover, usually less than 5% per year. The office appears to have beaten the S&P 500 for the past 20 years. Mr. Coolidge is a graduate of the Harvard Business School and Harvard College. He is a member of the Boston Security Analysts Society and the Boston Economic Club. Laury is an Honorary Trustee of the Boston Athenaeum, and the Peabody Essex Museum.
Research Interest
Minerva Biotechnologies is developing cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Our stem cell technology could transform the field of regenerative medicine.